AstraZeneca Pharma India reported a 33% rise in revenue to ₹2,275.6 crore for FY26. Profit after tax saw a significant jump. Oncology revenue led the growth, up 44%. The company also recommended a dividend of ₹36 per share.
AstraZeneca Pharma India Reports Strong FY26 Growth
Total Revenue: ₹2,275.6 crore (FY 2025-26)
Profit After Tax: ₹187.5 crore (FY 2025-26)
Reader Takeaway: Strong revenue and profit growth driven by oncology, but monitor rising debt and legal cases.
What just happened
AstraZeneca Pharma India Ltd. announced its financial results for the fiscal year 2025-26, reporting a total revenue of ₹2,275.6 crore, a significant increase of approximately 33% compared to ₹1,716.3 crore in FY 2024-25. Profit After Tax (PAT) also saw substantial improvement, reaching ₹187.5 crore from ₹115.7 crore in the previous fiscal year. The company's Board has proposed a dividend of ₹36 per share.
Why this matters
The robust revenue growth, particularly in key therapeutic areas like Oncology and Rare Disease, indicates strong market performance and effective product strategy. The significant PAT improvement suggests enhanced operational efficiency. The proposed dividend offers a direct return to shareholders, reflecting confidence in future performance.
The backstory
This fiscal year saw AstraZeneca Pharma India transition to an asset-lighter model with the cessation of manufacturing operations at its Bengaluru facility. Products have been successfully transferred to other global sites, ensuring supply continuity. This strategic shift aims to optimize operational structure.
What changes now
The company has recommended the appointment of BSR & Co. LLP as its statutory auditors for a five-year term. Workforce numbers have adjusted to 760 from 802, reflecting the operational changes.
Risks to watch
Investors should note a rising Debt-Equity Ratio, which increased to 12.7% from 4.6%, largely due to lease liabilities. Inventory turnover has also decreased to 1.8 from 2.5. Ongoing legal disputes, including those with NHAI and a challenge against an NPPA demand notice for an anti-cancer drug, could pose future financial risks.
Peer comparison
While specific peer data is not provided in the filing, AstraZeneca's 33% revenue growth in FY26, driven by its specialized portfolios, indicates competitive performance in the Indian pharmaceutical market.
Context metrics (time-bound)
For FY 2025-26:
- Total Revenue: ₹2,275.6 crore
- Profit After Tax: ₹187.5 crore
- Oncology Revenue: ₹1,610.1 crore (up 44% YoY)
- Biopharmaceuticals Revenue: ₹524.3 crore (up 7.2% YoY)
- Rare Disease Revenue: ₹21.5 crore (up 7x YoY)
- Debt-Equity Ratio: 12.7%
- Inventory Turnover: 1.8
- Employee Count: 760
What to track next
Investors will be keen to observe the impact of the asset-lighter model on future profitability and operational efficiency. Monitoring the progress of ongoing legal and regulatory cases will be crucial for assessing potential financial risks. The company's ability to sustain growth in its key therapy areas will also be a key focus.